Jan H. Terheyden

Jan 29, 2024 | onlinelibrary.wiley.com | Zhichao Wu |Lauren Hodgson |Robyn Guymer |Jan H. Terheyden

1 INTRODUCTION A major challenge in the evaluation of new interventions to slow or prevent the development of late age-related macular degeneration (AMD) complications in its early stages is the need for large and lengthy trials given the slowly progressive nature of this disease.1, 2 Biomarkers that could be used to identify high-risk individuals to target in such trials, and/or act as earlier surrogate endpoints for progression to the conventional, gold-standard clinical endpoint of...